Bryan, Garnier & Co acts as Joint Bookrunner of a private placement with US and European Investors raising €18 Million for Oryzon

Bryan, Garnier & Co acts as Joint Bookrunner of a private placement with US and European Investors raising €18 Million for Oryzon

News published on April Monday 24, 2017
Share on

Context

  • Oryzon Genomics is a clinical stage biopharmaceutical company developing innovative therapies in the field of epigenetics
  • A scientifically and clinically validated epigenetic platform with two therapeutic programs in clinical development having multiple indication opportunities
  • Ozyzon Genomics has signed a global strategic partnership with ROCHE valued at $500M for its lead program
  • ORY-1001, a LSD1 program in clinical trials for leukemia and small cell lung cancer
  • ORY 2001, an unencumbered LSD1-MAOB program, is set to enter phase IIA in Alzheimer’s Disease, Multiple Sclerosis and Huntington’s Disease
  • Oryzon Genomics needed to strengthen its cash position ahead of planned developments in neurodegenerative diseases and more generally to fund its R&D activities
  • Additionally the company wanted to expand its international shareholder base 

Transaction

  • Bryan, Garnier & Co acted as joint book runner alongside Guggenheim Securities, LLC
  • The shares were sold at a price of EUR 3.20 per share corresponding to a 17.9% discount to last price
  • The capital increase was oversubscribed and raised gross proceeds of approximately EUR 18.2 million
  • The offering was marketed to institutional investors specialized in healthcare and life sciences from the US, Spain and the rest of Europe
  • The majority of the funds were raised from international investors, reinforcing and diversifying the company’s shareholder base

About Oryzon

Founded   in   2000   in   Barcelona,   Spain,   Oryzon is   a   clinical   stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point  it  is  decided  on  a case-by-case  basis  to  either  keep  the  development  in-house  or  to  partner  or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts.

www.oryzon.com

Deal team

Olivier Garnier
Co-Founder & Managing Partner
T: +33 1 56 68 75 29
 
Hervé Ronin
Partner, Healthcare
T: +33 1 70 36 57 22

Pierre Kiecolt-Wahl
Managing Director, ECM
T: +1 56 68 75 17

Brigitte de Lima
Director, Healthcare
T: +44 207 332 2545

Christian Finan
Director, Healthcare
T: +33 1 56 68 75 30


The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities